The immune response to AIDS virus infection: Good, bad, or both?

Journal of Clinical Investigation

Volumn 113, Issue 6, 2004, Pages 808-810

  Deeks, Steven G ^a   Walker, Bruce D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN SPECIFICITY; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; VIRAL LOAD;

EID: 2142713131     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200421318     Document Type: Review

References (18)

1. + T cells. Nature. 417:95-98.
2. Hellerstein, M.K., et al. 2003. Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J. Clin. Invest. 112:956-966. doi:10.1172/JCI200317533.
3. Silvestri, G., and Feinberg, M.B. 2003. Turnover of lymphocytes and conceptual paradigms in HIV infection. J. Clin. Invest. 112:821-824. doi:10.1172/JCI200319799.
4. + T-cell depletion in HIV infection: are we closer to understanding the cause? Nat. Med. 8:319-323.
5. + T lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18:332-340.
6. + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 187;1534-1543.
7. Silvestri, G., et al. 2003. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity. 18:441-452.
8. Broussard, S.R., et al. 2001. Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease. J. Virol. 75:2262-2275.
9. + T cells in control of SIV replication. J. Clin. Invest. 113:836-845. doi:10.1172/JCI200419442.
10. Rey-Cuille, M.A., et al. 1998. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J. Virol. 72:3872-3886,
11. Chakrabarti, L.A., et al. 2000. Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. J. Virol. 74:1209-1223.
12. Trachrenberg, E., et al. 2003. Advantage of rare HLA supertype in HIV disease progression. Nat. Med. 9:928-935.
13. Goulder, P.J., et al. 2001. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature. 412:334-338.
14. Moore, C.B., et al. 2002. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296:1439-1443.
15. Brander, C., and Walker, B.D. 2003. Gradual adaptation of HIV to human host populations: good or bad news? Nat. Med. 9:1359-1362.
16. Rizzardi, G.P., et al. 2002. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J. Clin. Invest. 109:681-688. doi:10.1172/JCI200214522.
17. + T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J. Infect. Dis. 185:315-323.
18. Deeks, S.G. et al. 2004. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J. Infect. Dis. 189:312-321.